- Private clinical-phase focused tumor microenvironment (TME) oncology biopharma company
- Novel proprietary platform technology targets hexokinase 2 (HK2)/VDAC link, a key metabolic regulator of proliferation
- Re-establish apoptosis
- Re-establish immune response in tumor environment
- Bring back Cells to normal Metabolism and Glycolysis
- Lead Drug 1 tuvatexib (VDA-1102) is in Clinical Phase 2
- Phase 2b in cutaneous SCC i.e actinic keratosis (AK) : successful.
- Needs 2C to test new permeability enhanced formulation/protocol
- Phase 2 in cutaneous T-cell lymphoma (CTCL): Ongoing
- Lead Drug 2 VDA 1275: A new chemical family discovered through Artificial Intelligence (A.I) analysis based on researched mode of action (MOA)
- more than 100x more active, created for systemic use by IV, IM, Per-Os
- In advanced pre-clinical for use as stand alone in solid tumors
- solid tumors and tumor microenvironment: On going R&D for use in synergy in CAR-T and other Immunological and Cell based treatment
